Imaging of the striatal and extrastriatal dopamine transporter with 18F-LBT-999: Quantification, biodistribution, and radiation dosimetry in nonhuman primates

Journal of Nuclear Medicine

Volumn 52, Issue 8, 2011, Pages 1313-1321

  Varrone, Andrea ^a   Stepanov, Vladimir ^a   Nakao, Ryuji ^a   Tóth, Miklós ^a   Gulyás, Balázs ^a   Emond, Patrik ^b   Deloye, Jean Bernard ^c   Vercouillie, Johnny ^b   Stabin, Michael G ^d   Jonsson, Cathrine ^a   Guilloteau, Denis ^b   Halldin, Christer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c Academisch Centrum Kinder en Jeugdpsychiatrie Curium   (France)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Dopamine transporter; PET; Radiobiology dosimetry; Radiotracer tissue kinetics; Reference tissue method

Indexed keywords

DOPAMINE TRANSPORTER; METHYL 8 (4 FLUORO BUT 2 EN 1 YL) 3 (4 TOLYL) 8 AZABICYCLO[3.2.1]OCTANE 2 CARBOXYLATE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOSIMETRY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG PROTEIN BINDING; FEMALE; MESENCEPHALON; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; THALAMUS; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; COCAINE; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLUORINE RADIOISOTOPES; MACACA MULATTA; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOISOTOPES; RADIOMETRY; THALAMUS; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 80051682570     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.089953     Document Type: Article

References (28)

1. Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol. 2004;61:641-644. (Pubitemid 38637678)
2. Ciliax BJ, Drash GW, Staley JK, et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol. 1999;409:38-56. (Pubitemid 29242784)
3. Varrone A, Halldin C. Molecular imaging of the dopamine transporter. J Nucl Med. 2010;51:1331-1334.
4. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57:229-238. (Pubitemid 40187366)
5. 11C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res. 2009;43:1219-1223.
6. Chalon S, Hall H, Saba W, et al. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4′-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. J Pharmacol Exp Ther. 2006;317:147-152.
7. Emond P, Guilloteau D, Chalon S. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter. CNS Neurosci Ther. 2008;14:47-64.
8. 11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. Bioorg Med Chem. 2006;14:1115-1125.
9. 18F]LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET. J Labelled Comp Radiopharm. 2006;49:687-698.
10. 18F]LBT-999: a selective radioligand for the visualization of the dopamine transporter with PET. J Labelled Comp Radiopharm. 2007;50:716-723.
11. 11C]LBT- 999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse. 2007;61:17-23.
12. 18F]-LBT-999, a selective ligand for PET examination of the dopamine transporter. Paper presented at: European Association of Nuclear Medicine (EANM); September 30-October 4, 2006; Athens.
13. Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. Special report: the 1996 guide for the care and use of laboratory animals. ILAR J. 1997;38:41-48.
14. 18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol. 2005;32:109-116.
15. 11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl). 1993;113:149-156.
16. Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639-1650.
17. Saleem KS, Logothesis NK. A Combined MRI and Histology Atlas of the Rhesus Monkey Brain in Stereotaxic Coordinates. 1st ed. Oxford, U.K.: Academic Press; 2007.
18. Melchitzky DS, Lewis DA. Tyrosine hydroxylase- and dopamine transporterimmunoreactive axons in the primate cerebellum: evidence for a lobular- and laminar-specific dopamine innervation. Neuropsychopharmacology. 2000;22:466-472. (Pubitemid 30145614)
19. 123I] epidepride binding to striatal and extrastriatal dopamine D2 receptors. Synapse. 1999;34:290-304.
20. Carson RE. Parameter estimation in PET. In: Phelps M, Schelbert H, eds. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and the Heart. New York, NY: Raven Press; 1986:287-346.
21. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
22. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539. (Pubitemid 47301451)
23. 11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33:657-668.
24. 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med. 2006;47:520-527.
25. 18F-FPCIT in human subjects. J Nucl Med. 2003;44:961-966.
26. 18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. J Nucl Med. 2007;48:100-107.
27. Deloar HM, Fujiwara T, Shidahara M, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1998;25:565-574. (Pubitemid 28297830)
28. Verbruggen A, Coenen HH, Deverre JR, et al. Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging. 2008;35:2144-2151.